Skip to content
Triangle logo TriangleGet started
← Melanoma

HEALTH PROFESSIONAL · SOURCE READING

Combination signal transduction inhibitor therapy plus anti–PD-L1 therapy

Source: Melanoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 2, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Treatment Option Overview for Melanoma / Systematic Treatment for Unresectable Stage III, Stage IV, and Recurrent Disease / Signal transduction inhibitors

The triplet regimen of cobimetinib (MEK inhibitor), vemurafenib (BRAF kinase inhibitor), and atezolizumab (PD-L1 inhibitor) is an FDA-approved regimen. A phase III study showed improved PFS over the combination of cobimetinib and vemurafenib.[32] However, there was not a significant difference in OS between the arms of the study and there was a higher rate of toxicities in the combination arm. As such, this regimen is not commonly used.

Source links and citations

Publication references

Read the original reference and check its publication notices.

Preserved source evidence · Not medical advice